Response to BRAF/MEK inhibition after progression with BRAF inhibition in a patient with anaplastic pleomorphic xanthoastrocytoma

Faiz Hussain, Craig Michael Horbinski, Steven J. Chmura, Bakhtiar Yamini, Rimas Vincas Lukas*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Pleomorphic xanthoastrocytoma (PXA) is a rare primary central nervous system tumor which frequently harbors mutations in BRAF. Anaplastic PXA follow a more aggressive course than their nonanaplastic counterparts. We present the case of an anaplastic PXA initially treated with the BRAF inhibitor vemurafenib. After progression of disease the MEK inhibitor trametinib was added to the regimen leading to radiographic improvement. The rationale for combined BRAF and MEK inhibition in PXA is reviewed.

Original languageEnglish (US)
Pages (from-to)163-166
Number of pages4
JournalNeurologist
Volume23
Issue number5
DOIs
StatePublished - Sep 1 2018

Keywords

  • BRAF
  • MEK
  • PXA
  • pleomorphic xanthoastrocytoma
  • trametinib
  • vemurafenib

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'Response to BRAF/MEK inhibition after progression with BRAF inhibition in a patient with anaplastic pleomorphic xanthoastrocytoma'. Together they form a unique fingerprint.

Cite this